TrialNature communications2025

Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial.

Fang Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.